Quick Answer
Inmune Bio, Inc. reported Total Assets of $32.35 million for the year ending 2025.
- Inmune Bio, Inc. showed a decrease of -18.2% in Total Assets from 2024 to 2025.
- This data is from Inmune Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $23.64 million | Q2 2019: $27.53 million | Q3 2019: $25.40 million | Q1 2020: $23.68 million | Q2 2020: $23.05 million | Q3 2020: $42.82 million | Q1 2021: $65.87 million | Q2 2021: $60.70 million | Q3 2021: $107.67 million | Q1 2022: $94.35 million | Q2 2022: $87.81 million | Q3 2022: $83.80 million | Q1 2023: $73.98 million | Q2 2023: $69.72 million | Q3 2023: $62.70 million | Q1 2024: $46.83 million | Q2 2024: $52.45 million | Q3 2024: $52.78 million | Q1 2025: $37.80 million | Q2 2025: $37.68 million | Q3 2025: $33.36 million.
- Over the full 9 years of available data (2017 to 2025), Inmune Bio, Inc.'s Total Assets has grown by 75.7%.
- Historical annual values: Fiscal year 2025: $32.35 million | Fiscal year 2024: $39.56 million | Fiscal year 2023: $57.00 million | Fiscal year 2022: $81.80 million | Fiscal year 2021: $99.95 million | Fiscal year 2020: $40.66 million | Fiscal year 2019: $24.47 million | Fiscal year 2018: $17.36 million | Fiscal year 2017: $18.41 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: